CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.

Autor: Ruggiero E; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Carnevale E; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Prodeus A; Intellia Therapeutics, Cambridge, MA 02139, USA., Magnani ZI; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Camisa B; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Merelli I; San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy.; National Research Council, Institute for Biomedical Technologies, Segrate, Italy., Politano C; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Stasi L; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Potenza A; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy.; School of Medicine and Surgery, Milano-Bicocca University, 20126 Milan, Italy., Cianciotti BC; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Manfredi F; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy.; Vita-Salute San Raffaele University, 20132 Milan, Italy., Di Bono M; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Vago L; Immunogenetics, Leukemia Genomics and Immunobiology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy.; Hematology and Bone Marrow Transplantation Unit, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Tassara M; Immunohematology and Transfusion Medicine Unit, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Mastaglio S; Hematology and Bone Marrow Transplantation Unit, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Ponzoni M; Vita-Salute San Raffaele University, 20132 Milan, Italy.; Pathology Unit, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Sanvito F; Pathology Unit, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Liu D; Intellia Therapeutics, Cambridge, MA 02139, USA., Balwani I; Intellia Therapeutics, Cambridge, MA 02139, USA., Galli R; Neural Stem Cell Biology Unit, Division of Neurosciences, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Genua M; Genomics of the Innate Immune System Unit, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Ostuni R; Vita-Salute San Raffaele University, 20132 Milan, Italy.; Genomics of the Innate Immune System Unit, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Doglio M; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., O'Connell D; Intellia Therapeutics, Cambridge, MA 02139, USA., Dutta I; Intellia Therapeutics, Cambridge, MA 02139, USA., Yazinski SA; Intellia Therapeutics, Cambridge, MA 02139, USA., McKee M; Intellia Therapeutics, Cambridge, MA 02139, USA., Arredouani MS; Intellia Therapeutics, Cambridge, MA 02139, USA., Schultes B; Intellia Therapeutics, Cambridge, MA 02139, USA., Ciceri F; Vita-Salute San Raffaele University, 20132 Milan, Italy.; Hematology and Bone Marrow Transplantation Unit, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy., Bonini C; Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Ospedale San Raffaele Scientific Institute, 20132 Milan, Italy.; Vita-Salute San Raffaele University, 20132 Milan, Italy.

Publikováno v: Science translational medicine [Sci Transl Med] 2022 Feb 09; Vol. 14 (631), pp. eabg8027. Date of Electronic Publication: 2022 Feb 09.

Localized protein biotinylation at DNA damage sites identifies ZPET, a repressor of homologous recombination.

Autor: Moquin DM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Genois MM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Zhang JM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Ouyang J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Yadav T; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Buisson R; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Yazinski SA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Tan J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Boukhali M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Gagné JP; Centre de Recherche du CHU de Quebec, Laval University, Quebec, Quebec G1V 4G2, Canada., Poirier GG; Centre de Recherche du CHU de Quebec, Laval University, Quebec, Quebec G1V 4G2, Canada., Lan L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Haas W; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA., Zou L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.

Publikováno v: Genes & development [Genes Dev] 2019 Jan 01; Vol. 33 (1-2), pp. 75-89. Date of Electronic Publication: 2018 Dec 19.

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.

Autor: Yazinski SA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Comaills V; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Buisson R; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Genois MM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Nguyen HD; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Ho CK; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Todorova Kwan T; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.; Howard Hughes Medical Institute, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA., Morris R; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Lauffer S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.; Massachusetts General Hospital Gillette Center, Massachusetts General Hospital, Boston, Massachusetts 02115, USA., Nussenzweig A; Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA., Ramaswamy S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Benes CH; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Haber DA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.; Howard Hughes Medical Institute, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA., Maheswaran S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA., Birrer MJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.; Massachusetts General Hospital Gillette Center, Massachusetts General Hospital, Boston, Massachusetts 02115, USA., Zou L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

Publikováno v: Genes & development [Genes Dev] 2017 Feb 01; Vol. 31 (3), pp. 318-332. Date of Electronic Publication: 2017 Feb 27.

The BRCA1-interacting protein Abraxas is required for genomic stability and tumor suppression.

Autor: Castillo A; Department of Genetics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Paul A; Department of Genetics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Genes and Development Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA., Sun B; Department of Genetics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Huang TH; Department of Biochemistry and Molecular Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Genes and Development Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA., Wang Y; Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Yazinski SA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA., Tyler J; Department of Biochemistry and Molecular Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Li L; Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., You MJ; Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Zou L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA., Yao J; Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Wang B; Department of Genetics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Genes and Development Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA. Electronic address: bwang3@mdanderson.org.

Publikováno v: Cell reports [Cell Rep] 2014 Aug 07; Vol. 8 (3), pp. 807-17. Date of Electronic Publication: 2014 Jul 24.

PRP19 transforms into a sensor of RPA-ssDNA after DNA damage and drives ATR activation via a ubiquitin-mediated circuitry.

Autor: Maréchal A; Massachusetts General Hospital Cancer Center Harvard Medical School Charlestown, MA 02129., Li JM; Department of Biochemistry and Molecular Biology The University of Texas Health Science Center at Houston Houston, TX 77030., Ji XY; Massachusetts General Hospital Cancer Center Harvard Medical School Charlestown, MA 02129., Wu CS; Massachusetts General Hospital Cancer Center Harvard Medical School Charlestown, MA 02129., Yazinski SA; Massachusetts General Hospital Cancer Center Harvard Medical School Charlestown, MA 02129., Nguyen HD; Massachusetts General Hospital Cancer Center Harvard Medical School Charlestown, MA 02129., Liu S; Massachusetts General Hospital Cancer Center Harvard Medical School Charlestown, MA 02129., Jiménez AE; Massachusetts General Hospital Cancer Center Harvard Medical School Charlestown, MA 02129., Jin J; Department of Biochemistry and Molecular Biology The University of Texas Health Science Center at Houston Houston, TX 77030., Zou L; Massachusetts General Hospital Cancer Center Harvard Medical School Charlestown, MA 02129.; Department of Pathology Massachusetts General Hospital Harvard Medical School Boston, MA 02114.

Publikováno v: Molecular cell [Mol Cell] 2014 Jan 23; Vol. 53 (2), pp. 235-246. Date of Electronic Publication: 2013 Dec 12.